


## BIZ 114

Cat. No.:	HY-135808		
CAS No.:	2099120-74-6		
Molecular Formula:	C <sub>24</sub> H <sub>40</sub> O <sub>3</sub>		
Molecular Weight:	376.57		
Target:	NF-κB		
Pathway:	NF-κB		
Storage:	Pure form	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

In Vitro	DMSO : 250 mg/mL (663.89 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	2.6555 mL	13.2777 mL	26.5555 mL
		5 mM	0.5311 mL	2.6555 mL	5.3111 mL
10 mM		0.2656 mL	1.3278 mL	2.6555 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.33 mg/mL (6.19 mM); Clear solution				
	2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.33 mg/mL (6.19 mM); Clear solution				

### BIOLOGICAL ACTIVITY

Description	BIZ 114 (Example 11) is a fatty acid derivative and potent inhibits the TNF-α activated NF-κB pathway. BIZ 114 has the potential to prevent and / or treat ophthalmic disorders such as retinal degenerative disorders and ocular inflammatory diseases <sup>[1]</sup> .
IC <sub>50</sub> & Target	NF-κB <sup>[1]</sup>
In Vitro	Polyunsaturated fatty acids and their metabolites are involved in many physiological and pathophysiological reactions and as such possess a range of important biological activities. They affect plasma lipids and lipid metabolism. They are incorporated into cell membranes where they influence different cell functions. They are also involved in inflammatory diseases and they also influence and control gene expression. The fatty acid derivatives have the potential for treatment

---

and/or prevention of ophthalmic disorders, in particular retinal disorders such as age-related macular degeneration and diabetic retinopathy, and ocular inflammatory diseases<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## REFERENCES

---

[1]. Anne Kristin Holmeide. pid compounds and compositions and their ophthalmic use. WO2017093732A1.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA